Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Cyclerion Therapeutics files to offer 6.1M shares of common stock for holders  16:28
08/07/20
08/07
16:28
08/07/20
16:28
CYCN

Cyclerion Therapeutics

$4.35 /

+0.19 (+4.57%)

 
ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$4.35 /

+0.19 (+4.57%)

CYCN Cyclerion Therapeutics
$4.35 /

+0.19 (+4.57%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$4.35 /

+0.19 (+4.57%)

Monday
Earnings
Cyclerion Therapeutics reports Q2 revenue $0.7M vs. $1.6M last year » 09:27
08/03/20
08/03
09:27
08/03/20
09:27
CYCN

Cyclerion Therapeutics

$3.81 /

-0.23 (-5.69%)

Net loss was…

Net loss was approximately $20M for the second quarter of 2020, as compared to $32M for the second quarter of 2019. "We are looking forward to upcoming top line results from both our translational pharmacology study for IW-6463, the first brain-penetrant sGC stimulator to enter clinical development, and our STRONG olinciguat Phase 2 study for sickle cell disease. Both programs have the potential to provide a fundamentally new approach for patients with limited therapeutic options today", said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.81 /

-0.23 (-5.69%)

CYCN Cyclerion Therapeutics
$3.81 /

-0.23 (-5.69%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
Over a week ago
Syndicate
Cyclerion Therapeutics files $150M mixed securities shelf  17:15
07/24/20
07/24
17:15
07/24/20
17:15
CYCN

Cyclerion Therapeutics

$3.45 /

-0.17 (-4.70%)

 
ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$3.45 /

-0.17 (-4.70%)

CYCN Cyclerion Therapeutics
$3.45 /

-0.17 (-4.70%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
Hot Stocks
Cyclerion Therapeutics announces presentation on biomarker data » 07:03
07/17/20
07/17
07:03
07/17/20
07:03
CYCN

Cyclerion Therapeutics

$4.83 /

-0.13 (-2.62%)

Cyclerion Therapeutics…

Cyclerion Therapeutics announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on "Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies" at the Annual Biomarkers in Alzheimer's Disease Summit that was held virtually on July 15, 2020. The presentation detailed the application of translational biomarkers to guide clinical activities for IW-6463, the Company's therapeutic candidate for CNS diseases. In preclinical studies, IW-6463 has demonstrated beneficial effects across four domains relevant to neurodegenerative diseases: cerebral blood flow, cellular bioenergetics, neuro-inflammation, and neuronal function. Cyclerion plans to develop IW-6463 in individuals with Alzheimer's disease with vascular pathology, as well as in MELAS, a genetically defined orphan disease. The Company is evaluating cerebrospinal fluid and plasma biomarkers and various imaging approaches to define optimal clinical endpoints.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$4.83 /

-0.13 (-2.62%)

CYCN Cyclerion Therapeutics
$4.83 /

-0.13 (-2.62%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$4.83 /

-0.13 (-2.62%)

Conference/Events
Cyclerion Therapeutics to host conference call » 07:55
07/09/20
07/09
07:55
07/09/20
07:55
CYCN

Cyclerion Therapeutics

$5.70 /

+0.3 (+5.56%)

Management holds a…

Management holds a conference call to discuss IW-6463 pre-clinical and Phase 1 clinical study data on July 9 at 8:15 am. Webcast Link

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

Conference/Events
Cyclerion Therapeutics to host conference call » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
CYCN

Cyclerion Therapeutics

$5.70 /

+0.3 (+5.56%)

Management holds a…

Management holds a conference call to discuss IW-6463 pre-clinical and Phase 1 clinical study data on July 9 at 8:15 am. Webcast Link

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$5.70 /

+0.3 (+5.56%)

Over a month ago
Conference/Events
Cyclerion Therapeutics to host conference call » 17:05
07/02/20
07/02
17:05
07/02/20
17:05
CYCN

Cyclerion Therapeutics

$5.86 /

+0.01 (+0.17%)

Management holds a…

Management holds a conference call to discuss IW-6463 pre-clinical and Phase 1 clinical study data on July 9 at 8:15 am. Webcast Link

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
CYCN Cyclerion Therapeutics
$5.86 /

+0.01 (+0.17%)

Over a quarter ago
Hot Stocks
Cyclerion closes enrollment on two ongoing clinical studies » 08:44
04/10/20
04/10
08:44
04/10/20
08:44
CYCN

Cyclerion Therapeutics

$2.76 /

-0.03 (-1.08%)

Cyclerion Therapeutics…

Cyclerion Therapeutics announced that it recently closed enrollment for both of its ongoing clinical studies. The company said, "We are looking forward to a catalyst-rich period in the coming months with top line results from both our translational pharmacology study for IW-6463, our brain-penetrant sGC stimulator designed to treat neurodegenerative diseases, and our olinciguat Phase 2 study for sickle cell disease. We also continue discussions on the out-licensing of praliciguat, a potential best-in-class therapeutic candidate for cardio-metabolic diseases. Recent published outcomes data from other groups provide compelling new support for the use of the sGC stimulator class in treating cardiometabolic diseases." It added, "The Company is tightly managing its spending. As of March 31, 2020, Cyclerion's preliminary unaudited cash, cash equivalents and restricted cash balance was approximately $72 million. Cyclerion anticipates that this cash will fund its operations into Q2 2021, excluding net cash flows from potential business development activities...The Company cannot give any assurances as to the potential impact of the pandemic on its operations, clinical trials, corporate development discussions and other activities. Cyclerion is working closely with its clinical trial sites and investigators to deliver its ongoing and planned trials in a manner consistent with the safety of study participants and healthcare professionals. Cyclerion does not anticipate any drug product disruption for its clinical trials and is taking steps to mitigate any disruptions of clinical supply materials to trial participants."

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$2.76 /

-0.03 (-1.08%)

02/26/20 Spin-Off Research
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research
08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
06/03/19 Credit Suisse
Cyclerion Therapeutics initiated with a Neutral at Credit Suisse
Downgrade
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research » 10:04
02/26/20
02/26
10:04
02/26/20
10:04
CYCN

Cyclerion Therapeutics

$4.30 /

+0.03 (+0.70%)

Spin-Off Research…

Spin-Off Research downgraded Cyclerion Therapeutics to Hold from Buy with a $5 price target.

ShowHide Related Items >><<
CYCN Cyclerion Therapeutics
$4.30 /

+0.03 (+0.70%)

08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
06/03/19 Credit Suisse
Cyclerion Therapeutics initiated with a Neutral at Credit Suisse
Options
Ten new option listings and two option delistings on January 23rd » 08:30
01/23/20
01/23
08:30
01/23/20
08:30
AKRO

Akero Therapeutics

$23.34 /

+0.46 (+2.01%)

, AQST

Aquestive Therapeutics

$3.90 /

-0.2 (-4.88%)

, CYCN

Cyclerion Therapeutics

$3.75 /

+0.23 (+6.53%)

, ITRN

Ituran

$25.31 /

-0.51 (-1.98%)

, OBSV

ObsEva

$4.39 /

-0.09 (-2.01%)

, PHAS

PhaseBio

$5.43 /

-0.2 (-3.55%)

, PHAT

Phathom Pharmaceuticals

$38.10 /

+1.29 (+3.50%)

, STOK

Stoke Therapeutics

$23.87 /

+0.52 (+2.23%)

, XP

XP Inc.

$42.45 /

+1.845 (+4.54%)

, MDR

McDermott

$0.70 /

+ (+0.00%)

, TOO

Changed to ALIN

$1.54 /

-0.005 (-0.32%)

New option listings for…

New option listings for January 23rd include Akero Therapeutics Inc (AKRO), Aquestive Therapeutics Inc (AQST), Cyclerion Therapeutics Inc (CYCN), Ituran (ITRN), McDermott International Inc (MDRIQ), ObsEva (OBSV), PhaseBio Pharmaceuticals Inc (PHAS), Phathom Pharmaceuticals Inc (PHAT), Stoke Therapeutics Inc (STOK), and XP Inc (Class A Stock) (XP). Option delistings effective January 23rd include McDermott International Inc (MDR) and Teekay Offshore Partners LP (Units) (TOO).

ShowHide Related Items >><<
AKRO Akero Therapeutics
$23.34 /

+0.46 (+2.01%)

07/15/19 Evercore ISI
Akero Therapeutics initiated with an Outperform at Evercore ISI
07/15/19 Jefferies
Akero Therapeutics initiated with a Buy at Jefferies
07/15/19 JPMorgan
Akero Therapeutics initiated with an Overweight at JPMorgan
07/15/19 Roth Capital
Akero Therapeutics initiated with a Buy at Roth Capital
AQST Aquestive Therapeutics
$3.90 /

-0.2 (-4.88%)

01/13/20 Lake Street
Aquestive competitor approval may bring overhang, says Lake Street
12/27/19 Lake Street
Aquestive Therapeutics price target lowered to $10 from $11 at Lake Street
12/17/19 Wedbush
Aquestive Therapeutics price target lowered to $34 from $37 at Wedbush
12/02/19 JMP Securities
Aquestive Therapeutics NDA filing a positive sign, says JMP Securities
CYCN Cyclerion Therapeutics
$3.75 /

+0.23 (+6.53%)

08/21/19 Spin-Off Research
Cyclerion Therapeutics upgraded to Buy from Hold at Spin-Off Research
06/03/19 Credit Suisse
Cyclerion Therapeutics initiated with a Neutral at Credit Suisse
ITRN Ituran
$25.31 /

-0.51 (-1.98%)

05/16/19 Barclays
Ituran initiated with an Overweight at Barclays
OBSV ObsEva
$4.39 /

-0.09 (-2.01%)

12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
12/02/19 H.C. Wainwright
ObsEva price target lowered to $36 from $44 at H.C. Wainwright
11/08/19 Credit Suisse
ObsEva downgraded to Neutral from Outperform at Credit Suisse
07/29/19 Credit Suisse
ObsEva price target lowered to $16 from $24 at Credit Suisse
PHAS PhaseBio
$5.43 /

-0.2 (-3.55%)

01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
12/18/19 Citi
Citi calls PhaseBio most undervalued SMid-Biotech stock
10/03/19 H.C. Wainwright
PhaseBio initiated with a Buy at H.C. Wainwright
09/09/19 Stifel
PhaseBio selloff on prasugrel vs. ticagrelor study 'well overdone,' says Stifel
PHAT Phathom Pharmaceuticals
$38.10 /

+1.29 (+3.50%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
STOK Stoke Therapeutics
$23.87 /

+0.52 (+2.23%)

12/17/19 Wedbush
Stoke Therapeutics initiated with an Outperform at Wedbush
11/12/19
Fly Intel: Top five analyst initiations
11/12/19 BTIG
Stoke Therapeutics initiated with a Buy at BTIG
10/25/19 H.C. Wainwright
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
XP XP Inc.
$42.45 /

+1.845 (+4.54%)

01/06/20 Morgan Stanley
Morgan Stanley starts XP Inc. at Overweight with $45 price target
01/06/20 Morgan Stanley
XP Inc. initiated with an Overweight at Morgan Stanley
01/06/20 JPMorgan
XP Inc. initiated with an Overweight at JPMorgan
01/05/20 Goldman Sachs
XP Inc. initiated with a Neutral at Goldman Sachs
MDR McDermott
$0.70 /

+ (+0.00%)

01/13/20 Bernstein
McDermott initiated with an Underperform at Bernstein
11/05/19 Citi
McDermott bankruptcy risk is rising, Citi says, while cutting target to $1.60
09/20/19 Credit Suisse
McDermott's plans to sell Lummus 'a last resort,' says Credit Suisse
09/19/19 Citi
Citi sees working capital unwind as 'legitimate risk' for McDermott
TOO Changed to ALIN
$1.54 /

-0.005 (-0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.